Oklo experienced a dramatic share movement at the end of 2025, falling 21.5% in December after a 46% decline between November and December as investors digested profit-taking following a 700% run-up earlier in the year. Concerns over a $1.5 billion at-the-market equity offering and potential dilution weighed on sentiment, but the company’s stock has already recouped those losses in early 2026, rallying nearly 46% in just two weeks on the back of major strategic announcements.

In January 2026, Oklo signed a multi-billion-dollar agreement with Meta to develop a 1.2 gigawatt fast-fission nuclear power campus in Ohio. Meta will provide funding to cover pre-construction work beginning this year, with the first Aurora reactor scheduled to come online as early as 2030. The deal ties long-term data-center power demand to contracted revenue streams for Oklo, significantly de-risking its first large-scale commercial deployment.

Oklo secured a Department of Energy agreement to design, construct and operate a radioisotope pilot plant under the DOE’s reactor pilot program. This marks a critical step toward domestic production of medical radioisotopes—currently almost entirely imported—and validates Oklo’s fast-fission technology beyond electricity generation. The pilot plant will leverage Oklo’s reactor design to produce isotopes for cancer therapy and diagnostic imaging, with construction slated to begin later this year.

In December, Oklo won safety approval from the DOE to assemble its first fuel fabrication facility, positioning it as one of the first U.S. companies to produce fuel for next-generation microreactors. Combined with its partnerships and pilot programs, this vertical integration—from fuel production to power generation—underscores Oklo’s potential to capture both energy and specialty isotope markets. While investors must navigate volatility, the company’s secured funding and governmental backing lay a foundation for accelerating revenue growth into the next decade.